MSI Solid Tumors Refractory to PD1/PDL1 Antibody Monotherapy
1 clinical trials · Condition
◉ Watch MSI Solid Tumors Refractory to PD1/PDL1 Antibody Monotherapy
| Record | Firm | Date |
|---|---|---|
| A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy (NCT06549907) | Peking University Cancer Hospital & Institute | 2024-01-10 |
Track MSI Solid Tumors Refractory to PD1/PDL1 Antibody Monotherapy automatically
Every clearance here is in the API, with alerts when new ones post.